These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28932090)

  • 1. New botanical drug, HL tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: A placebo-controlled, randomized, phase II trial.
    Jeong JY; Sohn JH; Baek YH; Cho YK; Kim Y; Kim H
    World J Gastroenterol; 2017 Aug; 23(32):5977-5985. PubMed ID: 28932090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease.
    Safadi R; Konikoff FM; Mahamid M; Zelber-Sagi S; Halpern M; Gilat T; Oren R;
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2085-91.e1. PubMed ID: 24815326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease.
    Pacifico L; Bonci E; Di Martino M; Versacci P; Andreoli G; Silvestri LM; Chiesa C
    Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):734-41. PubMed ID: 26026214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of Zataria multiflora Boiss. (Shirazi thyme) on nonalcoholic fatty liver disease and insulin resistance: A randomized double-blind placebo-controlled clinical trial.
    Zamani N; Shams M; Nimrouzi M; Zarshenas MM; Abolhasani Foroughi A; Fallahzadeh Abarghooei E; Fattahi MR
    Complement Ther Med; 2018 Dec; 41():118-123. PubMed ID: 30477827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective Effects of Chaihu Shugan San () on Nonalcoholic Fatty Liver Disease in Rats with Insulin Resistance.
    Jiang WN; Li D; Jiang T; Guo J; Chen YF; Wang J; Zhou Y; Yang CY; Tang CP
    Chin J Integr Med; 2018 Feb; 24(2):125-132. PubMed ID: 27164963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resveratrol does not benefit patients with nonalcoholic fatty liver disease.
    Chachay VS; Macdonald GA; Martin JH; Whitehead JP; O'Moore-Sullivan TM; Lee P; Franklin M; Klein K; Taylor PJ; Ferguson M; Coombes JS; Thomas GP; Cowin GJ; Kirkpatrick CM; Prins JB; Hickman IJ
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2092-103.e1-6. PubMed ID: 24582567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial.
    Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    BMC Complement Altern Med; 2019 Mar; 19(1):59. PubMed ID: 30871514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention and treatment effect of total flavonoids in Stellera chamaejasme L. on nonalcoholic fatty liver in rats.
    Wang Y; Li JY; Han M; Wang WL; Li YZ
    Lipids Health Dis; 2015 Aug; 14():85. PubMed ID: 26242978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease.
    Kim W; Kim BG; Lee JS; Lee CK; Yeon JE; Chang MS; Kim JH; Kim H; Yi S; Lee J; Cho JY; Kim SG; Lee JH; Kim YJ
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1073-1083. PubMed ID: 28225186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study.
    Oscarsson J; Önnerhag K; Risérus U; Sundén M; Johansson L; Jansson PA; Moris L; Nilsson PM; Eriksson JW; Lind L
    J Clin Lipidol; 2018; 12(6):1390-1403.e4. PubMed ID: 30197273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease.
    Boyraz M; Pirgon Ö; Dündar B; Çekmez F; Hatipoğlu N
    J Clin Res Pediatr Endocrinol; 2015 Jun; 7(2):121-7. PubMed ID: 26316434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
    Wah Kheong C; Nik Mustapha NR; Mahadeva S
    Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1940-1949.e8. PubMed ID: 28419855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.
    Schwimmer JB; Lavine JE; Wilson LA; Neuschwander-Tetri BA; Xanthakos SA; Kohli R; Barlow SE; Vos MB; Karpen SJ; Molleston JP; Whitington PF; Rosenthal P; Jain AK; Murray KF; Brunt EM; Kleiner DE; Van Natta ML; Clark JM; Tonascia J; Doo E;
    Gastroenterology; 2016 Dec; 151(6):1141-1154.e9. PubMed ID: 27569726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.
    Joy TR; McKenzie CA; Tirona RG; Summers K; Seney S; Chakrabarti S; Malhotra N; Beaton MD
    World J Gastroenterol; 2017 Jan; 23(1):141-150. PubMed ID: 28104990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
    Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
    Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial.
    Stefan N; Ramsauer M; Jordan P; Nowotny B; Kantartzis K; Machann J; Hwang JH; Nowotny P; Kahl S; Harreiter J; Hornemann S; Sanyal AJ; Stewart PM; Pfeiffer AF; Kautzky-Willer A; Roden M; Häring HU; Fürst-Recktenwald S
    Lancet Diabetes Endocrinol; 2014 May; 2(5):406-16. PubMed ID: 24795254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
    Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
    J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
    Loomba R; Kayali Z; Noureddin M; Ruane P; Lawitz EJ; Bennett M; Wang L; Harting E; Tarrant JM; McColgan BJ; Chung C; Ray AS; Subramanian GM; Myers RP; Middleton MS; Lai M; Charlton M; Harrison SA
    Gastroenterology; 2018 Nov; 155(5):1463-1473.e6. PubMed ID: 30059671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.